Eli Lilly has embarked on the most ambitious manufacturing expansion in pharmaceutical history, pledging $27 billion to construct four new production facilities across the United States and investing billions more in European and Asian operations. At the heart of this expansion is orforglipron, Lilly once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, expected to receive regulatory approval in 2026.
The scope of this investment reflects a fundamental shift in how major pharma companies think about manufacturing. Rather than relying on fragmented global supply chains, Lilly is vertically integrating at unprecedented scale.
Lilly U.S. expansion includes a $6 billion facility in Huntsville, Alabama for small-molecule and peptide API manufacturing; a $6.5 billion orforglipron production site in Texas; a $5 billion bioconjugate and monoclonal antibody facility in Virginia; and a $1.2 billion expansion of oral solid dosage capacity in Puerto Rico. A $3.5 billion injectable drug facility in Pennsylvania will produce next-generation obesity therapies.
The Alabama site, which breaks ground in 2026, will incorporate machine learning, AI, and digital automation into operations. This aligns with Lilly partnership with NVIDIA to build the company most powerful supercomputer for drug discovery.
Beyond U.S. borders, Lilly is developing a $3 billion orforglipron manufacturing facility in the Netherlands and investing $1 billion to expand its biologics site in Limerick, Ireland. The company also announced a $3 billion commitment to build localized production capacity in China at its Suzhou facility.
This geographic diversification serves a dual purpose: meeting local regulatory requirements and hedging against geopolitical risks. As tariff threats on pharmaceutical imports intensify, companies with distributed manufacturing are better positioned.
Lilly currently outsources approximately 60 to 70 percent of its peptide API production to CDMOs. As Lilly brings orforglipron production in-house, the balance will shift but external partners will remain essential for overflow capacity and specialized process steps.
Equipment suppliers for bioreactors and chromatography systems will see sustained demand. Raw material suppliers face volume increases. CDMOs with peptide synthesis or high-potency API capabilities can position themselves as strategic partners. The GLP-1 era is a manufacturing revolution reshaping the pharmaceutical supply chain for years to come.
